Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Vascular Pharmacology
  4. Fast Track Articles
  5. Fast Track Article
image of The Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Morbidly Obese Patients on Anticoagulation: A Systematic Review and Meta-Analysis

Abstract

Introduction

Current guidelines and consensus statements advise caution in using direct oral anticoagulants (DOACs) for morbidly obese patients with body mass index (BMI) >40 kg/m2, indicating warfarin as the most studied treatment.

Methods

We systematically searched databases from their inception to January 4, 2024, to identify studies that evaluated the effectiveness and safety of DOACs compared to warfarin in patients with BMI >40 kg/m2 and atrial fibrillation (AF) or venous thromboembolism (VTE). The outcomes of all-cause mortality, major and minor bleeding, stroke/systematic embolism (SE), VTE, and their composite endpoint were analyzed using a random-effects model.

Results

This meta-analysis included 24 studies and 119,960 morbidly obese patients with AF or VTE on oral anticoagulation therapy: 51,363 on DOACs (43%) . (57%) 68,597 on warfarin. DOAC use was significantly associated with lower all-cause mortality and major bleeding risk compared to warfarin. Although the risk of composite endpoint, stroke/SE, and VTE was lower in the DOAC group, no statistically significant difference was observed, indicating no superiority of warfarin compared to DOAC use. The risk of minor bleeding events, hemorrhagic stroke, and ischemic stroke was lower in the DOAC compared to the warfarin group. The same trend favoring DOACs over warfarin in all assessed endpoints was observed in the subgroup analysis based on anticoagulation indication (AF or VTE).

Conclusion

Our findings have documented a potentially more effective and safer profile of DOACs compared to warfarin in morbidly obese patients regardless of the indication for anticoagulation.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611330090250130075810
2025-02-11
2025-06-01

  • From This Site

    /content/journals/cvp/10.2174/0115701611330090250130075810
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Lavie C.J. Arena R. Alpert M.A. Milani R.V. Ventura H.O. Management of cardiovascular diseases in patients with obesity. Nat. Rev. Cardiol. 2018 15 1 45 56 10.1038/nrcardio.2017.108 28748957
    [Google Scholar]
  2. Goossens G.H. The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function. Obes. Facts 2017 10 3 207 215 10.1159/000471488 28564650
    [Google Scholar]
  3. Kunutsor S.K. Obesity or adipokines—which should be targeted for venous thromboembolism prevention? J. Thromb. Haemost. 2023 21 2 195 197 10.1016/j.jtha.2022.11.008 36775413
    [Google Scholar]
  4. Mahajan R. Lau D.H. Brooks A.G. Shipp N.J. Manavis J. Wood J.P.M. Finnie J.W. Samuel C.S. Royce S.G. Twomey D.J. Thanigaimani S. Kalman J.M. Sanders P. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J. Am. Coll. Cardiol. 2015 66 1 1 11 10.1016/j.jacc.2015.04.058 26139051
    [Google Scholar]
  5. Koskinas K.C. Craenenbroeck V.E.M. Antoniades C. Blüher M. Gorter T.M. Hanssen H. Marx N. McDonagh T.A. Mingrone G. Rosengren A. Prescott E.B. Aboyans V. Lundqvist B.C. Nielsen J.C. Donal E. Döhner W. Ferrini M. Halvorsen S. Hassager C. Huber K. James S. Leclercq C. Linde C. McEvoy J.W. McMurray J. Mihaylova B. Mindham R. Petersen S. Piepoli M. Rakisheva A. Rosselló X. Szymański P. Uchmanowicz I. Vrints C. Windecker S. Witkowski A. Zeppenfeld K. Obesity and cardiovascular disease: An ESC clinical consensus statement. Eur. Heart J. 2024 45 38 4063 4098 10.1093/eurheartj/ehae508 39210706
    [Google Scholar]
  6. Kalani C. Awudi E. Alexander T. Udeani G. Surani S. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Hosp. Pract. 2019 47 4 181 185 10.1080/21548331.2019.1674586 31580732
    [Google Scholar]
  7. Reilly P.A. Lehr T. Haertter S. Connolly S.J. Yusuf S. Eikelboom J.W. Ezekowitz M.D. Nehmiz G. Wang S. Wallentin L. RE-LY Investigators The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol. 2014 63 4 321 328 10.1016/j.jacc.2013.07.104 24076487
    [Google Scholar]
  8. Martin K. Westendorf B.J. Davidson B.L. Huisman M.V. Sandset P.M. Moll S. Use of the direct oral anticoagulants in obese patients: Guidance from the SSC of the ISTH. J. Thromb. Haemost. 2016 14 6 1308 1313 10.1111/jth.13323 27299806
    [Google Scholar]
  9. Kearon C. Akl E.A. Ornelas J. Blaivas A. Jimenez D. Bounameaux H. Huisman M. King C.S. Morris T.A. Sood N. Stevens S.M. Vintch J.R.E. Wells P. Woller S.C. Moores L. Antithrombotic therapy for VTE disease. Chest 2016 149 2 315 352 10.1016/j.chest.2015.11.026 26867832
    [Google Scholar]
  10. Phillippe H.M. Wright B.M. Bowerman K.E. Andrus M.R. Pharmacist interventions regarding the appropriateness of apixaban, rivaroxaban, dabigatran, and warfarin in a university-affiliated outpatient clinic. J. Pharm. Technol. 2016 32 245 252
    [Google Scholar]
  11. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. Chou R. Glanville J. Grimshaw J.M. Hróbjartsson A. Lalu M.M. Li T. Loder E.W. Wilson M.E. McDonald S. McGuinness L.A. Stewart L.A. Thomas J. Tricco A.C. Welch V.A. Whiting P. Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst. Rev. 2021 10 1 89 10.1186/s13643‑021‑01626‑4 33781348
    [Google Scholar]
  12. Hicks K.A. Mahaffey K.W. Mehran R. Nissen S.E. Wiviott S.D. Dunn B. Solomon S.D. Marler J.R. Teerlink J.R. Farb A. Morrow D.A. Targum S.L. Sila C.A. Hai M.T.T. Jaff M.R. Joffe H.V. Cutlip D.E. Desai A.S. Lewis E.F. Gibson C.M. Landray M.J. Lincoff A.M. White C.J. Brooks S.S. Rosenfield K. Domanski M.J. Lansky A.J. McMurray J.J.V. Tcheng J.E. Steinhubl S.R. Burton P. Mauri L. O’Connor C.M. Pfeffer M.A. Hung H.M.J. Stockbridge N.L. Chaitman B.R. Temple R.J. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation 2018 137 9 961 972 10.1161/CIRCULATIONAHA.117.033502 29483172
    [Google Scholar]
  13. Spyropoulos A.C. Ashton V. Chen Y.W. Wu B. Peterson E.D. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. Thromb. Res. 2019 182 159 166 10.1016/j.thromres.2019.08.021 31493618
    [Google Scholar]
  14. Perales I.J. Agustin S.K. DeAngelo J. Campbell A.M. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann. Pharmacother. 2020 54 4 344 350 10.1177/1060028019886092 31672028
    [Google Scholar]
  15. Falk K. McComb M.N. Shapiro N.L. Uppuluri E.M. Prescribing pattern of oral anticoagulants in patients with obesity. J. Pharm. Pract. 2022 35 2 248 255 10.1177/0897190020969276 33138664
    [Google Scholar]
  16. Kushnir M. Choi Y. Eisenberg R. Rao D. Tolu S. Gao J. Mowrey W. Billett H.H. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: A single-centre, retrospective analysis of chart data. Lancet Haematol. 2019 6 7 e359 e365 10.1016/S2352‑3026(19)30086‑9 31133411
    [Google Scholar]
  17. Weir M.R. Chen Y.W. He J. Bookhart B. Campbell A. Ashton V. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. J. Diab. Compl. 2021 35 11 108029 10.1016/j.jdiacomp.2021.108029 34538715
    [Google Scholar]
  18. Kido K. Ngorsuraches S. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann. Pharmacother. 2019 53 2 165 170 10.1177/1060028018796604 30130979
    [Google Scholar]
  19. Peterson E.D. Ashton V. Chen Y.W. Wu B. Spyropoulos A.C. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am. Heart J. 2019 212 113 119 10.1016/j.ahj.2019.02.001 30981035
    [Google Scholar]
  20. Crouch A. Ng T.H. Kelley D. Knight T. Edwin S. Giuliano C. Multi‐center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy 2022 42 2 119 133 10.1002/phar.2655 34904263
    [Google Scholar]
  21. Cohen A.T. Pan S. Byon W. Ilyas B.S. Taylor T. Lee T.C. Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: Insights from amplify. Adv. Ther. 2021 38 6 3003 3018 10.1007/s12325‑021‑01716‑8 33890242
    [Google Scholar]
  22. Costa O.S. Westendorf B.J. Ashton V. Milentijevic D. Moore K.T. Bunz T.J. Coleman C.I. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: Analysis of electronic health record data. J. Thromb. Thrombolysis 2021 51 2 349 358 10.1007/s11239‑020‑02199‑0 32588288
    [Google Scholar]
  23. Alberts M.J. He J. Kharat A. Ashton V. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Am. J. Cardiovasc. Drugs 2022 22 4 425 436 10.1007/s40256‑021‑00520‑7 35092000
    [Google Scholar]
  24. Cohen A. Sah J. Lee T. Rosenblatt L. Hlavacek P. Emir B. Keshishian A. Yuce H. Luo X. Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity. J. Clin. Med. 2021 10 2 200 10.3390/jcm10020200 33429844
    [Google Scholar]
  25. Briasoulis A. Mentias A. Mazur A. Alvarez P. Leira E.C. ghan Sarrazin V.M.S. Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation. Cardiovasc. Drugs Ther. 2021 35 2 261 272 10.1007/s10557‑020‑07126‑2 33404923
    [Google Scholar]
  26. Perino A.C. Fan J. Schmitt S. Guo J.D. Hlavacek P. Din N. Kothari M. Pundi K. Russ C. Emir B. Turakhia M.P. Anticoagulation treatment and outcomes of venous thromboembolism by weight and body mass index: Insights from the veterans health administration. Circ. Cardiovasc. Qual. Outcomes 2021 14 11 e008005 10.1161/CIRCOUTCOMES.121.008005 34724801
    [Google Scholar]
  27. Barakat A.F. Jain S. Masri A. Alkukhun L. Senussi M. Sezer A. Wang Y. Thoma F. Bhonsale A. Saba S. Mulukutla S. Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories. JACC Clin. Electrophysiol. 2021 7 5 649 658 10.1016/j.jacep.2021.02.002 33812834
    [Google Scholar]
  28. Patil T. Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb. Res. 2020 192 124 130 10.1016/j.thromres.2020.04.015 32473496
    [Google Scholar]
  29. Weaver P. Ng T.H. Breeden T. Edwin S.B. Haan B. Giuliano C. Management of venous thromboembolism in morbid obesity with rivaroxaban or warfarin. Ann. Pharmacother. 2022 56 12 1315 1324 10.1177/10600280221089008 35505606
    [Google Scholar]
  30. Alotaibi S.N. Hasan H. Metwali H. Aseeri M. Comparing the efficacy and safety of apixaban versus warfarin in morbidly obese patients. Cureus 2022 14 10 e30303 10.7759/cureus.30303 36407232
    [Google Scholar]
  31. Lorenz M.A. Linneman T.W. Comparing safety and efficacy of direct oral anticoagulants versus warfarin in extreme obesity. J. Pharm. Pract. 2023 36 6 1375 1382 10.1177/08971900221116809 35938580
    [Google Scholar]
  32. Bianco C. Wen S. Cai Y. Finch C. Kimble W. Caccamo M. Novel oral anticoagulants are safe and effective for thromboembolic prophylaxis in obese patients with atrial fibrillation. J. Amer. College Cardiol. 2020 75 11 505
    [Google Scholar]
  33. Martin K.A. Lancki N. Li C. Eyster M.E. Sanfilippo K. Woller I.A. Woller S.C. Kreuziger L.B. Rosovsky R.P. DOAC compared with warfarin for VTE in patients with obesity: A retrospective cohort study conducted through the VENUS network. J. Thromb. Thrombolysis 2023 55 4 685 690 10.1007/s11239‑023‑02774‑1 36757644
    [Google Scholar]
  34. Pilkerton C.S. Adelman M. Crocetti E. Xiang J. Strick V. Ponte C.D. Direct oral anticoagulants: Probability of recurrent venous thromboembolism and bleeding risk in an obese population. Ann. Pharmacother. 2023 58 8 781 789 37994550
    [Google Scholar]
  35. Hattaway Q. Starr J.A. Pinner N.A. Direct oral anticoagulants for the treatment of venous thromboembolism in obesity. J. Pharm. Technol. 2023 39 6 269 273 10.1177/87551225231196748 37974596
    [Google Scholar]
  36. Martin K.A. Westendorf B.J. Davidson B.L. Huisman M.V. Sandset P.M. Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC subcommittee on control of anticoagulation. J. Thromb. Haemost. 2021 19 8 1874 1882 10.1111/jth.15358 34259389
    [Google Scholar]
  37. Zhao Y. Guo M. Li D. Xu W. Pan C. He C. Cui X. Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: An updated literature review. Clin. Appl. Thromb. Hemost. 2023 29 10760296231153638 10.1177/10760296231153638 36760080
    [Google Scholar]
  38. Joglar J.A. Chung M.K. Armbruster A.L. Benjamin E.J. Chyou J.Y. Cronin E.M. Deswal A. Eckhardt L.L. Goldberger Z.D. Gopinathannair R. Gorenek B. Hess P.L. Hlatky M. Hogan G. Ibeh C. Indik J.H. Kido K. Kusumoto F. Link M.S. Linta K.T. Marcus G.M. McCarthy P.M. Patel N. Patton K.K. Perez M.V. Piccini J.P. Russo A.M. Sanders P. Streur M.M. Thomas K.L. Times S. Tisdale J.E. Valente A.M. Wagoner V.D.R. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2024 149 1 e1 e156 10.1161/CIR.0000000000001193 38033089
    [Google Scholar]
  39. Kubitza D. Becka M. Zuehlsdorf M. Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 2007 47 2 218 226 10.1177/0091270006296058 17244773
    [Google Scholar]
  40. Fryar C Carroll M Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E-Stats. 2022 1 7
    [Google Scholar]
  41. Wang T.J. Parise H. Levy D. D’Agostino R.B. Sr Wolf P.A. Vasan R.S. Benjamin E.J. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004 292 20 2471 2477 10.1001/jama.292.20.2471 15562125
    [Google Scholar]
  42. Huxley R.R. Lopez F.L. Folsom A.R. Agarwal S.K. Loehr L.R. Soliman E.Z. Maclehose R. Konety S. Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in communities (ARIC) study. Circulation 2011 123 14 1501 1508 10.1161/CIRCULATIONAHA.110.009035 21444879
    [Google Scholar]
  43. Holst A.G. Jensen G. Prescott E. Risk factors for venous thromboembolism: Results from the copenhagen city heart study. Circulation 2010 121 17 1896 1903 10.1161/CIRCULATIONAHA.109.921460 20404252
    [Google Scholar]
  44. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The sirius study. Arch. Intern. Med. 2000 160 22 3415 3420 10.1001/archinte.160.22.3415 11112234
    [Google Scholar]
  45. Ageno W. Becattini C. Brighton T. Selby R. Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 2008 117 1 93 102 10.1161/CIRCULATIONAHA.107.709204 18086925
    [Google Scholar]
  46. Sagris M. Kokkinidis D.G. Lempesis I.G. Giannopoulos S. Rallidis L. Hurtado M.C. Bakoyiannis C. Nutrition, dietary habits, and weight management to prevent and treat patients with peripheral artery disease. Rev. Cardiovasc. Med. 2020 21 4 565 575 10.31083/j.rcm.2020.04.202 33388001
    [Google Scholar]
  47. Chopard R. Albertsen I.E. Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism. JAMA 2020 324 17 1765 1776 10.1001/jama.2020.17272 33141212
    [Google Scholar]
  48. Sandhu R.K. Ezekowitz J. Andersson U. Alexander J.H. Granger C.B. Halvorsen S. Hanna M. Hijazi Z. Jansky P. Lopes R.D. Wallentin L. The ‘obesity paradox’ in atrial fibrillation: Observations from the aristotle (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur. Heart J. 2016 37 38 2869 2878 10.1093/eurheartj/ehw124 27071819
    [Google Scholar]
  49. Patel M.R. Mahaffey K.W. Garg J. Pan G. Singer D.E. Hacke W. Breithardt G. Halperin J.L. Hankey G.J. Piccini J.P. Becker R.C. Nessel C.C. Paolini J.F. Berkowitz S.D. Fox K.A.A. Califf R.M. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011 365 10 883 891 10.1056/NEJMoa1009638 21830957
    [Google Scholar]
  50. Coons J.C. Albert L. Bejjani A. Iasella C.J. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism. Pharmacotherapy 2020 40 3 204 210 10.1002/phar.2369 31968126
    [Google Scholar]
  51. Thangjui S. Kewcharoen J. Yodsuwan R. Trongtorsak A. Thyagaturu H. Shrestha B. Winans A.R.M. Bischof E. Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: Systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. 2022 8 4 325 335 10.1093/ehjcvp/pvab026 33730164
    [Google Scholar]
  52. Mhanna M. Beran A. Abdouh A.A. Sajdeya O. Abdulsattar W. Srour O. Ayesh H. Alom M. Khuder S.A. Hamouda D. Assaly R. Direct oral anticoagulants versus warfarin in morbidly obese patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis. Am. J. Ther. 2021 28 5 e531 e539 10.1097/MJT.0000000000001403 34491953
    [Google Scholar]
  53. Patel S.M. Braunwald E. Steffel J. Boriani G. Palazzolo M.G. Antman E.M. Bohula E.A. Carnicelli A.P. Connolly S.J. Eikelboom J.W. Gencer B. Granger C.B. Morrow D.A. Patel M.R. Wallentin L. Ruff C.T. Giugliano R.P. Efficacy and safety of non–vitamin-k antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and body weight: An individual patient data meta-analysis of 4 randomized clinical trials of patients with atrial fibrillation. Circulation 2024 149 12 932 943 10.1161/CIRCULATIONAHA.123.066279
    [Google Scholar]
  54. Ee S.C.E. Rosario B.H. Mok Z.H. Tun M.H. Razali S.S.B.Y. Tan B.H. Warfarin versus direct oral anticoagulants in South Asian octogenarians: A retrospective review. Blood Coagul. Fibrinolysis 2023 34 5 319 326 10.1097/MBC.0000000000001233 37395223
    [Google Scholar]
  55. Kanaan D.M. Malloy R. Knowles D. Evaluation of patient characteristics linked to major bleeding events in patients prescribed direct oral anticoagulants. Clin. Appl. Thromb. Hemost. 2023 29 10760296231172765 10.1177/10760296231172765 37246422
    [Google Scholar]
  56. Cereda A. Lucreziotti S. Franchina A.G. Laricchia A. Regibus D.V. Conconi B. Carlà M. Spangaro A. Rocchetti M. Ponti L. Minardi A. Sala E. Sangiorgi G.M. Tumminello G. Barbieri L. Carugo S. Aseni P. Systematic review and meta-analysis of oral anticoagulant therapy in atrial fibrillation cancer patients. Cancers 2023 15 9 2574 10.3390/cancers15092574 37174043
    [Google Scholar]
/content/journals/cvp/10.2174/0115701611330090250130075810
Loading
The Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Morbidly Obese Patients on Anticoagulation: A Systematic Review and Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0115701611330090250130075810
/content/journals/cvp/10.2174/0115701611330090250130075810
/content/journals/cvp/10.2174/0115701611330090250130075810
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: anticoagulation ; Direct oral anticoagulants ; atrial fibrillation ; warfarin ; morbidly obese ; venous thromboembolism ; vitamin-K antagonist

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test